Compare HBM & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBM | NUVL |
|---|---|---|
| Founded | 1927 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.3B |
| IPO Year | 2005 | 2021 |
| Metric | HBM | NUVL |
|---|---|---|
| Price | $25.74 | $108.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | $25.00 | ★ $134.75 |
| AVG Volume (30 Days) | ★ 5.0M | 563.6K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.66 | N/A |
| Revenue Next Year | $14.54 | $1,235.73 |
| P/E Ratio | $21.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.98 | $63.56 |
| 52 Week High | $28.74 | $113.02 |
| Indicator | HBM | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 64.21 |
| Support Level | $23.27 | $97.94 |
| Resistance Level | $28.64 | $112.61 |
| Average True Range (ATR) | 0.90 | 3.65 |
| MACD | 0.55 | 0.63 |
| Stochastic Oscillator | 90.13 | 98.02 |
Hudbay Minerals Inc is a copper-focused critical minerals company with three long-life operations and a pipeline of copper growth projects in Canada, Peru, and the United States. Its operating portfolio includes the Constancia mine in Cusco (Peru), the Snow Lake operations in Manitoba (Canada), and the Copper Mountain mine in British Columbia (Canada). Copper is the primary metal produced by the company, which is complemented by gold, zinc, silver, and molybdenum production. Hudbay's growth pipeline includes the Copper World project and the Mason project in the USA, and the Llaguen project in Peru. The company's reportable segments are: Peru, which generates the maximum revenue, Manitoba, British Columbia, and Arizona. Geographically, it generates maximum revenue from China and Canada.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.